Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients.
about
Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendationsDiagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).Visceral leishmaniasis and HIV coinfection in the Mediterranean region.Atypical Presentation of PKDL due to Leishmania infantum in an HIV-Infected Patient with Relapsing Visceral Leishmaniasis.Update in the treatment of cutaneous leishmaniasis.Use of antimony in the treatment of leishmaniasis: current status and future directions.Therapeutic options for visceral leishmaniasis.Drug resistance in visceral leishmaniasis.Successful use of miltefosine and sodium stibogluconate, in combination, for the treatment of an HIV-positive patient with visceral leishmaniasis: a case report and brief review of the literature.Human immunodeficiency virus and leishmaniasis.Recurrent leishmaniasis in kidney transplant recipients: report of 2 cases and systematic review of the literature.Experience with miltefosine for persistent or relapsing visceral leishmaniasis in solid organ transplant recipients: A case series from Spain.Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients.Visceral leishmaniasis and HIV coinfection: current perspectives
P2860
Q28088410-33E4EE2E-5322-42EE-8204-AC5A11579AD6Q30275257-8C3B11E0-0082-4FDB-9BF0-9A760D00EA5DQ34075119-E3309B12-86AC-4C03-BDDD-EB06F353237EQ34114043-8385993A-B1E2-4E4B-84EA-937195F5E5A6Q34421618-5EC0429E-820C-4012-B8AC-F80EF3002A86Q35377767-B06812E2-C02A-48F9-A9CA-704CD82F7B0BQ37333942-FCC9E920-BF39-4FD9-A346-501276AE5AF9Q37407549-5B8BC837-4B25-4F90-8C7C-CF6DFDAD4B8EQ37543667-858DC7C6-EAA9-4412-9AF1-B68D83DDE752Q37798456-C4A68F74-6BFC-42B1-9F73-010BCE612D1EQ37833667-3EDE275C-E029-4BF8-96A3-A00BBED0F6E8Q39262349-E6BE3F11-69AF-48A3-9B31-9D1577ECDD8BQ47548487-EE5BED01-1379-431B-B4FE-426F37176734Q58562873-C667F671-D498-4A68-9DAC-42E48F90BDC9
P2860
Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Miltefosine for visceral leish ...... axis in HIV-infected patients.
@en
Miltefosine for visceral leish ...... axis in HIV-infected patients.
@nl
type
label
Miltefosine for visceral leish ...... axis in HIV-infected patients.
@en
Miltefosine for visceral leish ...... axis in HIV-infected patients.
@nl
prefLabel
Miltefosine for visceral leish ...... axis in HIV-infected patients.
@en
Miltefosine for visceral leish ...... axis in HIV-infected patients.
@nl
P2093
P2860
P1476
Miltefosine for visceral leish ...... axis in HIV-infected patients.
@en
P2093
A Meliço-Silvestre
Filomena Coelho
J Saraiva Da Cunha
Joaquim Oliveira
Nuno Marques
P2860
P304
P356
10.1080/00365540701787800
P577
2008-01-01T00:00:00Z